Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment | American Society of Clinical Oncology Educational Book
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer - Annals of Oncology
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
ESMO 2019: Updated Results from the Phase 3 SPARTAN Study, Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Pushing Ahead With New Treatments for Nonmetastatic Castration-Resistant Prostate Cancer
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
ESMO 2019: Updated Results from the Phase 3 SPARTAN Study, Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer
ARV-Trials.com
nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options
Pivotal Trials Efficacy Data | For HCPs | REYVOW® (lasmiditan)
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
An Overview of ERLEADA® (apalutamide) Efficacy, Safety and Patient-Reported Outcomes Based on the TITAN and SPARTAN Trials - Renal and Urology News
ESMO 2019: Apalutamide and Overall Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Updated Results From the Phase 3 SPARTAN Study
Updates and Insights on the Medical Science of Prostate Cancer (Transcript)
Treatment and trials in non-metastatic castration-resistant prostate cancer | Nature Reviews Urology
Case 1: SPARTAN Trial for Apalutamide in nmCRPC
nmCRPC - Optimal Care in Prostate Cancer - Text Module - Therapeutic Strategies in Prostate Cancer - Oncology - Clinical Care Options
Final Analysis of SPARTAN Study
ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract
The SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of an Investigational NRTI- and RTV-Sparing Regimen of Atazanavir (ATV) Experimental Dose of 300mg BID plus Raltegravir (RAL) 400mg BID (
Apalutamide and Overall Survival in Prostate Cancer - ScienceDirect
Managing Nonmetastatic Castration-resistant Prostate Cancer - European Urology
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
